Announcement on Obtaining Government Subsidies
Filed with SSE · · 1 page · Chinese
Chengdu Olymvax Biopharmaceuticals Inc. on 6ix
Earlier from Chengdu Olymvax Biopharmaceuticals
- Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
- Announcement on Shareholding Reduction Plan for Senior Management Members
- Announcement on Resolutions of the 4th Meeting of the 7th Board of Directors
- 2025 Semi-annual Report
- Announcement on Abnormal Fluctuations in Stock Trading
Later from Chengdu Olymvax Biopharmaceuticals
- Indicative Announcement on Planning to Issue H-shares and Listing on the Stock Exchange of Hong Kong Limited
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Announcement on Progress in the Acquisition of Minority Shareholders' Stock Rights of a Holding Subsidiary
- Announcement on Repurchase and Cancellation of the First Category Restricted Shares Initially Granted under the 2023 Restricted Stock Incentive Plan That Have Been Granted But Not Yet Released from Sales Restrictions
- Announcement on Voluntary Disclosure of Initiating Phase III Clinical Trial of the Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) and Enrolling the First Subject
Follow Chengdu Olymvax Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Olymvax Biopharmaceuticals